- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02553733
Effect of Beetroot Juice on Coronary Blood Flow and Walking Performance in PAD (HeartBeet)
Effects of Dietary Nitrate Supplementation on Coronary Blood Flow and Walking Performance in Peripheral Arterial Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Peripheral arterial disease (PAD) is a strong predictor of cardiovascular mortality and negatively affects functional capacity and quality of life for as many as 14 million patients in the U.S. alone. One open-label study showed that acute consumption of beetroot juice improved 6 min walk performance, reduced blood pressure, and enhanced leg muscle oxygenation in PAD patients. However, no studies have rigorously confirmed these findings in a double-blind manner, nor have the effects of this supplement been investigated (acutely or short-term) in the coronary circulation of PAD patients.
In addition to studying its effects on graded treadmill walking performance and consequent large artery vasodilation, the present study will examine the effects of short-term beetroot juice consumption (twice/day) on both coronary and leg vasodilator (graded calf flexion) and vasoconstrictor (isometric handgrip, voluntary apnea) responses in patients with PAD. Participants will randomly consume either nitrate-rich or nitrate-depleted beetroot juice with a 7 to 14 day wash-out period between. Effects of beetroot juice consumption on plasma nitrate, nitrite and methemoglobin will also be assessed.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Milton S. Hershey Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with peripheral arterial disease (PAD)
- Capable of giving informed consent
- Men and women age 21- 85 years
- Diagnosed with PAD (i.e., ankle-brachial index below 0.9)
- Fontaine stage II or less - no pain while resting
- Satisfactory history and physical exam
Exclusion Criteria:
- Children
- Pregnant or nursing women
- Patients taking nitroglycerine or nitrate preparations
- Patients taking phosphodiesterase inhibitors such as sildenafil or tadalafil
- Patients taking proton pump inhibitors
- Ejection fraction < 40%
- Uncontrolled hypertension
- Uncontrolled diabetes
- Myocardial infarction within past 6 months or unstable angina
- Severe lung disease (i.e., on supplemental oxygen or frequently use rescue inhalers)
- Abnormality in hemoglobin or hematocrit or methemoglobin
- Impaired renal function
- Impaired liver function
- History or diagnosis of Barrett's esophagus
- Known allergy to beetroot juice or lemon juice
- Inability to walk on a treadmill at a moderate pace (2.0 miles/hour)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Beetroot juice (Beet-It Organic Shot)
Subjects will consume 70 ml of beetroot juice (Beet-It Organic Shot) twice per day (morning, afternoon) for 5 to 7 days to assess the short term effects of this nitrate supplement on graded treadmill walking responses (day 4) and vasodilator/vasoconstrictor responses in the coronary and lower leg circulations (day 5 or 6 or 7).
On both study visits, subjects will consume their morning dose 1 hour 45 min before experiments begin.
|
This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
Other Names:
|
|
Placebo Comparator: Beetroot juice placebo (Beet-It Organic Placebo)
Subjects will consume 70 ml of beetroot juice placebo (Beet-It Organic Placebo) twice per day (morning, afternoon) for 5 to 7 days to assess the short term effects of this nitrate supplement on graded treadmill walking responses (day 4) and vasodilator/vasoconstrictor responses in the coronary and lower leg circulations (day 5 or 6 or 7).
On both study visits, subjects will consume their morning dose 1 hour 45 min before experiments begin.
|
This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed.
It is also bottled and supplied by James White Drinks (UK).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Exercise performance
Time Frame: 5 to 7 days after initiating daily ingestion of beetroot juice
|
Exercise capacity will be assessed using a graded treadmill walking test to peak exertion with expired gas analysis and determination of peak oxygen uptake, calf muscle oxygenation, blood pressure, claudication onset time, and peak walking time.
|
5 to 7 days after initiating daily ingestion of beetroot juice
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Coronary vascular function
Time Frame: 4 days after initiating daily ingestion of beetroot juice
|
Coronary artery (transthoracic ultrasound) blood flow responses to plantar flexion and handgrip exercise.
|
4 days after initiating daily ingestion of beetroot juice
|
|
Leg vascular function
Time Frame: 4 days after initiating daily ingestion of beetroot juice
|
Popliteal artery and near infrared spectroscopy (NIRS) responses to plantar flexion and handgrip exercise.
|
4 days after initiating daily ingestion of beetroot juice
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood measures of nitrate absorption and conversion
Time Frame: 4 to 7 days after initiating ingestion of beetroot juice
|
Venous blood will be withdrawn (venipuncture) for determination of plasma nitrate, nitrite and methemoglobin levels
|
4 to 7 days after initiating ingestion of beetroot juice
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Urs A Leuenberger, MD, Penn State University
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00003242
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaRecruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
Marissa JarosinskiTerminatedPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
OrbusNeichEucatech AG; Centre Européen de Recherche CardiovasculaireRecruitingPeripheral Arterial Disease | Peripheral Arterial Occlusive DiseaseSpain, Singapore, Belgium, Germany
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Wroclaw Medical UniversityPoznan University of Medical Sciences; Military Institute of Medicine National...RecruitingPeripheral Arterial Disease(PAD)Poland
-
BayerCompleted
-
University of NebraskaRecruitingPeripheral Arterial Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Peripheral Artery Occlusive DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
Clinical Trials on Beetroot juice
-
Oxford Brookes UniversityNot yet recruitingHypertension | Type 2 Diabetes Mellitus | Autonomic Nervous System DiseasesUnited Kingdom
-
University of CoimbraRecruitingDiabete Mellitus | Small Vessel Cerebrovascular DiseasePortugal
-
Bangor UniversityCompleted
-
Western Norway University of Applied SciencesCompleted
-
Universidad Francisco de VitoriaUniversity of Alcala; University of SevilleCompleted
-
University Hospital, GhentUniversity GhentTerminated
-
Queen Mary University of LondonCompleted
-
Gødstrup HospitalRecruitingHypertension | CKD - Chronic Kidney DiseaseDenmark
-
University of ManchesterCompleted
-
Wake Forest University Health SciencesCompletedStroke | Ischemic Stroke | Cerebrovascular AccidentUnited States